Is the thin layer of methyl aminolevulinate used during photodynamic therapy sufficient?

Photodermatol Photoimmunol Photomed. 2016 Mar;32(2):88-92. doi: 10.1111/phpp.12227. Epub 2015 Dec 15.

Abstract

Background: If the recommended 1.0 mm layer of methyl aminolevulinate (MAL) is used during photodynamic therapy (PDT) of large areas with multiple actinic keratoses (AK) huge amounts of cream are needed.

Objectives: To report the amount of MAL used for PDT of AK and basal cell carcinomas (BCC) in daily routine. The association of protoporphyrin IX (PpIX) fluorescence and thickness of MAL was investigated in a randomized paired study in healthy volunteers.

Methods: Amount of cream used per cm(2) during conventional and daylight PDT was recorded. In 16 healthy volunteers, 0.1 mm, 0.2 mm, 0.5 mm and 1.0 mm MAL cream were applied for 3 h on tape-stripped areas on each forearm randomized to light-permeable or light-impermeable occlusion. PpIX fluorescence was measured.

Results: Less than 0.4 mm MAL was used during PDT of BCC and 0.2 mm for AK. No difference in PpIX fluorescence was found between the different thicknesses of MAL using light-impermeable occlusion.

Conclusion: In daily routine <0.4 mm MAL was used during PDT of BCC and 0.1-0.2 mm MAL during PDT of AK. The recommended 1.0 mm MAL did not result in a higher accumulation of PpIX compared to thinner MAL layers after light-impermeable occlusion for 3 h.

Keywords: actinic keratoses; basal cell carcinoma; methyl aminolevulinate; photodynamic therapy; protoporphyrin IX fluorescence.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Aged
  • Aminolevulinic Acid / administration & dosage*
  • Female
  • Humans
  • Keratosis, Actinic / drug therapy*
  • Keratosis, Actinic / pathology
  • Male
  • Photochemotherapy / methods*
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology

Substances

  • Aminolevulinic Acid